Immuron granted patent for anti-influenza product
Wednesday, 02 March, 2011
Melbourne-based Immuron scored a win today with the granting of an Australian patent for its influenza prevention product, Imm-255.
The patent, issued by the Australian Patents Office, provides protection through to 2028.
Imm-255 uses dairy-derived polyclonal influenza-specific antibodies, which are applied to oral and respiratory surfaces.
The antibodies have to date shown positive results in treating and preventing influenza in mice and ferrets, including treating H1N1.
Once animal trials have concluded, Immuron intends to proceed towards clinical trials in humans.
Immuron's (ASX:IMC) stock dropped $0.004 to 7.1c in morning trading.
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
COVID vaccine candidate protects against multiple variants
By targeting features shared by a range of coronaviruses, the vaccine is designed to offer...
